Syquant Capital Sas Invests $2.33 Million in Hill-Rom Holdings, Inc. (NYSE:HRC)

Syquant Capital Sas acquired a new position in Hill-Rom Holdings, Inc. (NYSE:HRC) during the third quarter, according to its most recent filing with the SEC. The firm acquired 15,500 shares of the medical technology company’s stock, valued at approximately $2,325,000. Hill-Rom comprises approximately 1.4% of Syquant Capital Sas’ holdings, making the stock its 18th biggest holding.

Several other hedge funds have also modified their holdings of HRC. Panagora Asset Management Inc. grew its position in shares of Hill-Rom by 477.2% in the 2nd quarter. Panagora Asset Management Inc. now owns 392,394 shares of the medical technology company’s stock worth $44,572,000 after buying an additional 324,417 shares during the last quarter. Balyasny Asset Management LLC boosted its position in shares of Hill-Rom by 718.8% during the second quarter. Balyasny Asset Management LLC now owns 360,518 shares of the medical technology company’s stock valued at $40,951,000 after purchasing an additional 316,486 shares in the last quarter. Cooke & Bieler LP boosted its position in shares of Hill-Rom by 21.1% during the second quarter. Cooke & Bieler LP now owns 1,767,706 shares of the medical technology company’s stock valued at $200,794,000 after purchasing an additional 308,422 shares in the last quarter. Schroder Investment Management Group bought a new stake in shares of Hill-Rom during the first quarter valued at approximately $19,171,000. Finally, Victory Capital Management Inc. boosted its position in shares of Hill-Rom by 4.9% during the second quarter. Victory Capital Management Inc. now owns 3,651,810 shares of the medical technology company’s stock valued at $414,809,000 after purchasing an additional 171,077 shares in the last quarter. Hedge funds and other institutional investors own 76.45% of the company’s stock.

HRC has been the topic of several research reports. Morgan Stanley lowered Hill-Rom from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $148.00 to $156.00 in a research report on Sunday, September 19th. Robert W. Baird lowered Hill-Rom from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $150.00 to $156.00 in a research report on Friday, September 3rd. Stifel Nicolaus cut Hill-Rom from a “buy” rating to a “hold” rating and set a $155.00 price objective for the company. in a research note on Friday, November 5th. Bank of America cut Hill-Rom from a “buy” rating to a “neutral” rating and set a $130.00 price objective for the company. in a research note on Tuesday, August 10th. Finally, KeyCorp cut Hill-Rom from an “overweight” rating to a “sector weight” rating in a research note on Wednesday, September 8th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $144.00.

HRC stock opened at $155.50 on Thursday. Hill-Rom Holdings, Inc. has a 1-year low of $93.34 and a 1-year high of $156.22. The business has a fifty day moving average price of $152.89 and a 200-day moving average price of $133.81. The company has a debt-to-equity ratio of 0.97, a current ratio of 1.38 and a quick ratio of 1.05. The stock has a market capitalization of $10.27 billion, a P/E ratio of 41.80 and a beta of 0.54.

Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, November 5th. The medical technology company reported $1.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.47 by $0.20. Hill-Rom had a return on equity of 23.07% and a net margin of 8.23%. The firm had revenue of $797.90 million during the quarter, compared to analysts’ expectations of $752.97 million. During the same quarter in the previous year, the business earned $1.17 earnings per share. The company’s revenue was up 13.1% on a year-over-year basis. As a group, analysts anticipate that Hill-Rom Holdings, Inc. will post 6.44 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 31st. Stockholders of record on Wednesday, December 15th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Tuesday, December 14th. Hill-Rom’s dividend payout ratio is currently 25.81%.

In other news, SVP Mary Kay Ladone sold 2,018 shares of the business’s stock in a transaction on Thursday, November 11th. The stock was sold at an average price of $155.14, for a total value of $313,072.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.69% of the stock is owned by insiders.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions.

See Also: Trade Deficit

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.